Tokyo Tape
Sign in
← Fuso Pharmaceutical Industries

Annual report

4538.TEDINET S100R6DG
Period2022-04-01 → 2023-03-31
Filed2023-06-29
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 88
MetricValuePeriodScopeSource row
Revenue¥51.0bn2022-04-01 → 2023-03-31StandaloneNet sales
Revenue¥49.6bn2021-04-01 → 2022-03-31StandaloneNet sales
Revenue¥49.3bn2020-04-01 → 2021-03-31dStandaloneNet sales (5-year summary)
Revenue¥46.9bn2019-04-01 → 2020-03-31dStandaloneNet sales (5-year summary)
Revenue¥46.1bn2018-04-01 → 2019-03-31dStandaloneNet sales (5-year summary)
Operating income¥2.2bn2022-04-01 → 2023-03-31StandaloneOperating income
Operating income¥1.9bn2021-04-01 → 2022-03-31StandaloneOperating income
Ordinary income¥2.2bn2022-04-01 → 2023-03-31StandaloneOrdinary income
Ordinary income¥2.0bn2021-04-01 → 2022-03-31StandaloneOrdinary income
Ordinary income¥2.2bn2020-04-01 → 2021-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥1.1bn2019-04-01 → 2020-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥1.3bn2018-04-01 → 2019-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥2.2bn2022-04-01 → 2023-03-31StandaloneIncome before income taxes
Profit before tax¥1.9bn2021-04-01 → 2022-03-31StandaloneIncome before income taxes
Net income¥1.6bn2022-04-01 → 2023-03-31StandaloneProfit loss
Net income¥1.5bn2021-04-01 → 2022-03-31StandaloneProfit loss
Net income¥1.6bn2020-04-01 → 2021-03-31dStandaloneNet income loss (5-year summary)
Net income¥707m2019-04-01 → 2020-03-31dStandaloneNet income loss (5-year summary)
Net income¥894m2018-04-01 → 2019-03-31dStandaloneNet income loss (5-year summary)
Total assets¥72.5bnat 2023-03-31StandaloneAssets
Total assets¥69.3bnat 2022-03-31StandaloneAssets
Total assets¥69.9bnat 2021-03-31dStandaloneTotal assets (5-year summary)
Total assets¥69.2bnat 2020-03-31dStandaloneTotal assets (5-year summary)
Total assets¥71.7bnat 2019-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥36.8bnat 2023-03-31StandaloneLiabilities
Total liabilities¥34.8bnat 2022-03-31StandaloneLiabilities
Net assets / equity¥35.6bnat 2023-03-31StandaloneNet assets
Net assets / equity¥34.5bnat 2022-03-31StandaloneNet assets
Net assets / equity¥33.7bnat 2021-03-31dStandaloneNet assets
Net assets / equity¥32.3bnat 2020-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥32.8bnat 2019-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥8.0bnat 2023-03-31StandaloneCash and deposits
Cash and deposits¥7.3bnat 2022-03-31StandaloneCash and deposits
Cash & equivalents¥8.0bnat 2023-03-31StandaloneCash and cash equivalents
Cash & equivalents¥7.3bnat 2022-03-31StandaloneCash and cash equivalents
Cash & equivalents¥7.1bnat 2021-03-31dStandaloneCash and cash equivalents
Cash & equivalents¥7.3bnat 2020-03-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥4.8bnat 2019-03-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow¥2.9bn2022-04-01 → 2023-03-31StandaloneNet cash provided by used in operating activities
Operating cash flow¥3.5bn2021-04-01 → 2022-03-31StandaloneNet cash provided by used in operating activities
Operating cash flow¥3.2bn2020-04-01 → 2021-03-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥5.7bn2019-04-01 → 2020-03-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥2.1bn2018-04-01 → 2019-03-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥1.4bn2022-04-01 → 2023-03-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥1.6bn2021-04-01 → 2022-03-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥978m2020-04-01 → 2021-03-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.5bn2019-04-01 → 2020-03-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥2.4bn2018-04-01 → 2019-03-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow−¥813m2022-04-01 → 2023-03-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥1.7bn2021-04-01 → 2022-03-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥2.4bn2020-04-01 → 2021-03-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.8bn2019-04-01 → 2020-03-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥313m2018-04-01 → 2019-03-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥183.072022-04-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥169.092021-04-01 → 2022-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥183.182020-04-01 → 2021-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥80.592019-04-01 → 2020-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥101.962018-04-01 → 2019-03-31dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥702022-04-01 → 2023-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥602021-04-01 → 2022-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥602020-04-01 → 2021-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥602019-04-01 → 2020-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥802018-04-01 → 2019-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥4,064.76at 2023-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥3,936.7at 2022-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥3,839.54at 2021-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥3,681.46at 2020-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥3,742.48at 2019-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio49.2%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio49.8%at 2022-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio48.2%at 2021-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio46.7%at 2020-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio45.8%at 2019-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE4.6%2022-04-01 → 2023-03-31StandaloneRate of return on equity (5-year summary)
ROE4.3%2021-04-01 → 2022-03-31StandaloneRate of return on equity (5-year summary)
ROE4.9%2020-04-01 → 2021-03-31dStandaloneRate of return on equity (5-year summary)
ROE2.2%2019-04-01 → 2020-03-31dStandaloneRate of return on equity (5-year summary)
ROE2.7%2018-04-01 → 2019-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued9,451,169at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2022-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2021-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2020-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2019-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees1,314at 2023-03-31StandaloneNumber of employees
Employees1,344at 2022-03-31StandaloneNumber of employees
Employees1,356at 2021-03-31dStandaloneNumber of employees
Employees1,352at 2020-03-31dStandaloneNumber of employees
Employees1,347at 2019-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 2
SegmentItemPeriodValue
Pharmaceutical Businessreportable segmentemployeesat 2023-03-311259 pure
Real Estate Businessreportable segmentemployeesat 2023-03-311 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,075
ItemContextValueUnit
Proceeds from long term loans payable fin cfPrior1YearDuration_NonConsolidatedMember2890000000JPY
Proceeds from long term loans payable fin cfCurrentYearDuration_NonConsolidatedMember3536000000JPY
Repayment of long term loans payable fin cfPrior1YearDuration_NonConsolidatedMember-4032000000JPY
Repayment of long term loans payable fin cfCurrentYearDuration_NonConsolidatedMember-3819000000JPY
Purchase of treasury stock fin cfPrior1YearDuration_NonConsolidatedMember-2000000JPY
Purchase of treasury stock fin cfCurrentYearDuration_NonConsolidatedMember-3000000JPY
Repayments of lease obligations fin cfPrior1YearDuration_NonConsolidatedMember-1000000JPY
Repayments of lease obligations fin cfCurrentYearDuration_NonConsolidatedMember-1000000JPY
Cash dividends paid fin cfPrior1YearDuration_NonConsolidatedMember-525000000JPY
Cash dividends paid fin cfCurrentYearDuration_NonConsolidatedMember-525000000JPY
Other net fin cfPrior1YearDuration_NonConsolidatedMember0JPY
Other net fin cfCurrentYearDuration_NonConsolidatedMember0JPY
Net cash provided by used in financing activitiesPrior1YearDuration_NonConsolidatedMember-1671000000JPY
Net cash provided by used in financing activitiesCurrentYearDuration_NonConsolidatedMember-813000000JPY
Net increase decrease in cash and cash equivalentsPrior1YearDuration_NonConsolidatedMember273000000JPY
Net increase decrease in cash and cash equivalentsCurrentYearDuration_NonConsolidatedMember667000000JPY
Cash and cash equivalentsPrior2YearInstant_NonConsolidatedMember7074000000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember7347000000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember7347000000JPY
Cash and cash equivalentsCurrentYearInstant_NonConsolidatedMember8014000000JPY
Contract liabilitiesPrior1YearInstant_NonConsolidatedMember385000000JPY
Contract liabilitiesCurrentYearInstant_NonConsolidatedMember200000000JPY
Medicine department cost of sales inventoriesPrior1YearDuration_NonConsolidatedMember362000000JPY
Medicine department cost of sales inventoriesCurrentYearDuration_NonConsolidatedMember481000000JPY
Packing and transportation expenses sgaPrior1YearDuration_NonConsolidatedMember2163000000JPY
Packing and transportation expenses sgaCurrentYearDuration_NonConsolidatedMember2208000000JPY
Provision of allowance for doubtful accounts sgaPrior1YearDuration_NonConsolidatedMember-216000000JPY
Provision of allowance for doubtful accounts sgaCurrentYearDuration_NonConsolidatedMember－JPY
Salaries sgaPrior1YearDuration_NonConsolidatedMember2430000000JPY
Salaries sgaCurrentYearDuration_NonConsolidatedMember2388000000JPY
Provision for bonuses sgaPrior1YearDuration_NonConsolidatedMember402000000JPY
Provision for bonuses sgaCurrentYearDuration_NonConsolidatedMember398000000JPY
Provision for directors bonuses sgaPrior1YearDuration_NonConsolidatedMember23000000JPY
Provision for directors bonuses sgaCurrentYearDuration_NonConsolidatedMember21000000JPY
Provision for directors retirement benefits sgaPrior1YearDuration_NonConsolidatedMember16000000JPY
Provision for directors retirement benefits sgaCurrentYearDuration_NonConsolidatedMember11000000JPY
Retirement benefit expenses sgaPrior1YearDuration_NonConsolidatedMember331000000JPY
Retirement benefit expenses sgaCurrentYearDuration_NonConsolidatedMember326000000JPY
Depreciation sgaPrior1YearDuration_NonConsolidatedMember487000000JPY
Depreciation sgaCurrentYearDuration_NonConsolidatedMember379000000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember1442000000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember1353000000JPY
Research and development expenses included in general and administrative expenses and manufacturing cost for current periodPrior1YearDuration_NonConsolidatedMember1442000000JPY
Research and development expenses included in general and administrative expenses and manufacturing cost for current periodCurrentYearDuration_NonConsolidatedMember1353000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-06-29
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第100期(自　2022年４月１日　至　2023年３月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)扶桑薬品工業株式会社

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2022-03-31pass
balance sheet identitynon_consolidated 2023-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2021-03-31pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · operating cash flownon_consolidated 2021-04-01/2022-03-31pass
statement vs summary · operating cash flownon_consolidated 2022-04-01/2023-03-31pass
statement vs summary · revenuenon_consolidated 2021-04-01/2022-03-31pass
statement vs summary · revenuenon_consolidated 2022-04-01/2023-03-31pass
statement vs summary · total assetsnon_consolidated 2022-03-31pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass